Defiance Daily Target 2X Long NVO ETF(NVOX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$9.02
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NVOX

11/20/2026: NVOX (1-star) is currently NOT-A-BUY. Pass it for now.

The Defiance Daily Target 2X Long NVO ETF (NVOX) provides 2x daily leveraged exposure to the share price performance of Novo Nordisk A/S through swap agreements and derivatives. Its primary strengths lie in offering tactical traders a convenient tool for magnified daily exposure without requiring a margin account. However, it carries significant risks, including severe compounding decay over multi-day holds, a high 1.31% expense ratio, and total single-stock concentration. NVOX is strictly designed for sophisticated, active short-term market participants who closely monitor their positions and technical momentum signals.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitLeveraged daily products are built for short-term trading rather than long-term growth investing.
Momentum investorStrong fit while signal remains positiveActive momentum traders can use NVOX to amplify short-term upside moves in Novo Nordisk when technical signals are favorable.
Value investorWeak fitHigh expense ratios and daily reset mechanisms run counter to traditional value investing principles.
Dividend/Income investorWeak fitThe fund does not focus on generating income and is designed entirely for capital movement via leverage.
Low-risk investorWeak fitThe 2x daily leverage objective introduces extreme volatility and risk of rapid principal loss.

Investor Profile

Ideal Investor Profile

Sophisticated day traders or tactical short-term investors seeking amplified daily directional exposure to Novo Nordisk.

Suitability

Best suited for intraday or very short-term tactical trading rather than long-term buy-and-hold investing.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighDaily compounding and 2x leverage magnify price swings significantly compared to holding the underlying stock directly.
Market riskHighAdverse moves in Novo Nordisk shares directly translate to accelerated losses for the fund.
ConcentrationHighThe fund's performance is entirely tied to a single underlying security and sector.
Tracking/expenseMedium / highCompounding effects over periods longer than one day can cause divergence from a straight 2x multiple of the stock's multi-day return.
LiquidityMediumWhile tradeable, sudden drops in trading interest can impact execution costs during volatile sessions.
Business/sector qualityMedium / highThe fund is vulnerable to regulatory, competitive, or clinical setbacks impacting Novo Nordisk.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

NVOX exhibits extreme historical and implied volatility due to its 2x daily leverage target on a single high-profile equity.

Market Risk

Carries concentrated single-stock risk, making it completely susceptible to adverse developments affecting Novo Nordisk A/S.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
Single stockNovo Nordisk A/S ADR (NVO) — seeks 2x daily return100Provides leveraged exposure to the daily price fluctuations of pharmaceutical giant Novo Nordisk through derivative contracts.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type ETF
Historic Profit -44.81%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.